Vicki L. Sato - 01 Nov 2021 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
01 Nov 2021
Net transactions value
-$83,383
Form type
4
Filing time
03 Nov 2021, 17:30:16 UTC
Previous filing
20 Oct 2021
Next filing
12 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $83,383 -1,666 -1.3% $50.05 127,833 01 Nov 2021 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $50.00 to $50.11 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Includes 2,074 restricted stock units.